Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 6/20 | 0.34 |
| ▸ | NPC1 | O15118 | 5/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24008102 | 0.80 | KMT2A (0.44) | KMT2AALDH1A1GAAMAPTKDM4E | |
| SCHEMBL18989155 | 0.79 | — | — | |
| SCHEMBL18989156 | 0.79 | — | — | |
| SCHEMBL16611176 | 0.78 | ALDH1A1 (0.45) | KMT2AALDH1A1GAAMAPTKDM4E | |
| SCHEMBL16611174 | 0.78 | ALDH1A1 (0.45) | KMT2AALDH1A1GAAMAPTKDM4E | |
| SCHEMBL1406859 | 0.76 | KMT2A (0.58) | KMT2AALDH1A1GAAMAPTKDM4E | |
| SCHEMBL24008049 | 0.76 | KMT2A (0.43) | KMT2AALDH1A1GAAMAPTKDM4E | |
| SCHEMBL17525371 | 0.74 | KMT2A (0.52) | KMT2AALDH1A1GAAMAPTKDM4E | |
| SCHEMBL14990248 | 0.74 | KMT2A (0.52) | KMT2AALDH1A1GAAMAPTKDM4E | |
| SCHEMBL11947773 | 0.74 | KMT2A (0.52) | KMT2AALDH1A1GAAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2025-03-20 | — | — | US | disclosed |
| CN-114716381-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-114605327-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-114573510-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12220401-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| CN-114591242-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-114634447-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-113636978-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-113603645-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-11826351-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230372298-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11471441-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220062239-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12220401-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | KMT2A 688/4885ALDH1A1 4454/4885GAA 1044/4885 |
| US-20220062239-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | KMT2A 688/4885ALDH1A1 4454/4885GAA 1044/4885 |
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | KMT2A 688/4885ALDH1A1 4454/4885GAA 1044/4885 |
| US-11826351-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | KMT2A 688/4885ALDH1A1 4454/4885GAA 1044/4885 |
| US-11471441-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | KMT2A 688/4885ALDH1A1 4454/4885GAA 1044/4885 |
| US-20230372298-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | KMT2A 688/4885ALDH1A1 4454/4885GAA 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.